Schoenlaub Anna K, Hoeller Alexander, Hofer Sabine, Haberlandt Edda, Steichen-Gersdorf Elisabeth, Karall Daniela, Forster Dorottya, Scholl-Bürgi Sabine
Department of Pediatrics I Medical University of Innsbruck, Tyrolean State Hospitals Innsbruck Austria.
Division of Nutrition and Dietetics University Hospital Innsbruck Innsbruck Austria.
JIMD Rep. 2025 Mar 25;66(2):e70007. doi: 10.1002/jmd2.70007. eCollection 2025 Mar.
Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is a rare inborn disorder of metabolism leading to encephalopathy due to disturbed glucose transport via the blood-brain-barrier and consecutive energy deficit of the brain. Since ketone bodies can serve as an alternative fuel for the brain, ketogenic diet therapies (KDT) are the treatment of choice for these patients. KDT refers to all forms of nutrition that lead to the formation of ketone bodies. We describe a 15-year-old girl with GLUT1-DS who was effectively treated with a form of KDT, a modified Atkins diet (MAD), and developed type 1 diabetes. After correction of the initial diabetic ketoacidosis (DKA), insulin pump treatment was started while staying on MAD. With this treatment regimen, no further DKA episodes occurred within 2 years of follow-up, current HbA1c 6.9%. Treatment of GLUT1-DS by KDT and type 1 diabetes (T1D) by insulin at the same time is challenging but feasible. The initial manifestation phase of T1D is critical and is made even more difficult by an already performed KDT. Target ranges for blood glucose AND β-hydroxybutyrate levels must be defined to optimize the insulin dosage. Additionally, patients, families, and caregivers need to be aware of the risk of this particular metabolic situation.
1型葡萄糖转运体缺乏综合征(GLUT1-DS)是一种罕见的先天性代谢紊乱疾病,由于通过血脑屏障的葡萄糖转运受阻以及随之而来的大脑能量缺乏,导致脑病。由于酮体可以作为大脑的替代燃料,生酮饮食疗法(KDT)是这些患者的首选治疗方法。KDT是指所有导致酮体形成的营养形式。我们描述了一名15岁患有GLUT1-DS的女孩,她通过一种生酮饮食疗法——改良阿特金斯饮食(MAD)得到有效治疗,但随后发展为1型糖尿病。在纠正初始糖尿病酮症酸中毒(DKA)后,在继续采用MAD饮食的同时开始胰岛素泵治疗。采用这种治疗方案,在2年的随访期内未再发生DKA发作,目前糖化血红蛋白(HbA1c)为6.9%。同时采用KDT治疗GLUT1-DS和胰岛素治疗1型糖尿病(T1D)具有挑战性,但可行。T1D的初始表现阶段至关重要,而已经实施的KDT会使其更加困难。必须确定血糖和β-羟基丁酸水平的目标范围,以优化胰岛素剂量。此外,患者、家庭和护理人员需要意识到这种特殊代谢情况的风险。